Mayne Pharma debuts $80M solid dose plant in North Carolina

The company expects to introduce more than 20 products and double its manufacturing volumes at the Greenville site. (Pixabay)

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

Construction on the 126,000-square-foot plant began two years ago. The plant more than quadruples Mayne’s capacity to produce oral solid-dose products in the U.S. to well over 1 billion doses and will allow for the manufacture of potent compounds and modified-release bead/pellet products, the company said.

Mayne scooped up 42 products from Teva and Allergan in 2016 as those two companies were looking to offload assets as part of an effort to win antitrust clearance for Teva’s $40.5 billion buyout of Allergan’s generics business. Mayne, which said it was focusing on U.S. generics growth, also bought 37 marketed generics plus 5 that were, at the time, under review at the FDA.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

“This new Greenville facility will greatly enhance our internal capacity and capability to support the mid- to long-term growth potential we see for our business and allows us to manufacture in the United States advanced drug delivery technologies that until today were only available in our Australian facility,” Scott Richards, Mayne’s chief executive, said in a statement. “The new plant will enable us to better control our supply chain, serve our customers better and reduce product costs.”

Richards added that in the next few years the company expects to introduce more than 20 products and double its manufacturing volumes at the Greenville site.

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.